~ Buy the TAUVID (flortaucipir f-18) Drug Profile, 2024 PDF Report in the Report Store ~

TAUVID Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Tauvid, and when can generic versions of Tauvid launch?

Tauvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-six patent family members in sixteen countries.

The generic ingredient in TAUVID is flortaucipir f-18. One supplier is listed for this compound. Additional details are available on the flortaucipir f-18 profile page.

DrugPatentWatch^® Generic Entry Outlook for Tauvid

Tauvid was eligible for patent challenges on May 28, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 26, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for TAUVID?
What are the global sales for TAUVID?
What is Average Wholesale Price for TAUVID?

Summary for TAUVID

International Patents:	26
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	9
Patent Applications:	9
What excipients (inactive ingredients) are in TAUVID?	TAUVID excipients list
DailyMed Link:	TAUVID at DailyMed

Drug patent expirations by year for TAUVID

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TAUVID

Generic Entry Date for TAUVID^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up NDA: 212123 Dosage: SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TAUVID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Cleveland Clinic	Phase 1
Avid Radiopharmaceuticals	Phase 2
Avid Radiopharmaceuticals	Phase 1

See all TAUVID clinical trials

US Patents and Regulatory Information for TAUVID

TAUVID is protected by one US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TAUVID is ⤷ Sign Up.

This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TAUVID

Imaging agents for detecting neurological dysfunction
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

FDA Regulatory Exclusivity protecting TAUVID

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-001	May 28, 2020		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		⤷ Sign Up
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-002	May 28, 2020		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-001	May 28, 2020		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-002	May 28, 2020		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for TAUVID

When does loss-of-exclusivity occur for TAUVID?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 12381042
Patent: Carboline and carbazole based imaging agents for detecting neurological dysfunction
Estimated Expiration: ⤷ Sign Up

Canada

Patent: 15390
Patent: NOUVEAUX AGENTS D IMAGERIE POUR LA DETECTION D UNE DYSFONCTION NEUROLOGIQUE (NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION)
Estimated Expiration: ⤷ Sign Up

Patent: 73963
Patent: AGENTS D'IMAGERIE A BASE DE CARBOLINE ET DE CARBAZOLE POUR LA DETECTION DE DYSFONCTION NEUROLOGIQUE (CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION)
Estimated Expiration: ⤷ Sign Up

China

Patent: 4781234
Patent: Carboline and carbazole based imaging agents for detecting neurological dysfunction
Estimated Expiration: ⤷ Sign Up

Patent: 7011342
Patent: 用于检测神经功能障碍的基于咔啉和咔唑的成像剂 (CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION)
Estimated Expiration: ⤷ Sign Up

Colombia

Patent: 31359
Patent: Agentes de imagen para detectar disfunción neurológica
Estimated Expiration: ⤷ Sign Up

Croatia

Patent: 0220401
Estimated Expiration: ⤷ Sign Up

Denmark

Patent: 47558
Estimated Expiration: ⤷ Sign Up

European Patent Office

Patent: 47558
Patent: NOUVEAUX AGENTS D'IMAGERIE POUR LA DÉTECTION D'UNE DYSFONCTION NEUROLOGIQUE (NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION)
Estimated Expiration: ⤷ Sign Up

Patent: 99763
Patent: Nouveaux agents d'imagerie pour la détection d'un dysfonctionnement neurologique (Novel imaging agents for detecting neurological dysfunction)
Estimated Expiration: ⤷ Sign Up

Patent: 52572
Patent: AGENTS D'IMAGERIE À BASE DE CARBOLINE ET DE CARBAZOLE POUR LA DÉTECTION DE DYSFONCTION NEUROLOGIQUE (CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION)
Estimated Expiration: ⤷ Sign Up

Hungary

Patent: 58352
Estimated Expiration: ⤷ Sign Up

Japan

Patent: 76206
Estimated Expiration: ⤷ Sign Up

Patent: 11512354
Estimated Expiration: ⤷ Sign Up

Patent: 15517572
Patent: 神経機能障害を検出するための造影剤
Estimated Expiration: ⤷ Sign Up

Lithuania

Patent: 47558
Estimated Expiration: ⤷ Sign Up

Poland

Patent: 47558
Estimated Expiration: ⤷ Sign Up

Portugal

Patent: 47558
Estimated Expiration: ⤷ Sign Up

Slovenia

Patent: 47558
Estimated Expiration: ⤷ Sign Up

South Korea

Patent: 1609504
Estimated Expiration: ⤷ Sign Up

Patent: 100135235
Patent: NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION
Estimated Expiration: ⤷ Sign Up

Patent: 150002854
Patent: CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION
Estimated Expiration: ⤷ Sign Up

Spain

Patent: 92830
Estimated Expiration: ⤷ Sign Up

Patent: 07992
Estimated Expiration: ⤷ Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TAUVID around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009102498		⤷ Sign Up
Slovenia	2247558		⤷ Sign Up
Portugal	2247558		⤷ Sign Up
Croatia	P20220401		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Indicators of Generic Entry

AI Research Assistant

Questions you can ask:

Summary for TAUVID

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TAUVID

Recent Clinical Trials for TAUVID

Patents protecting TAUVID

FDA Regulatory Exclusivity protecting TAUVID

When does loss-of-exclusivity occur for TAUVID?

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TAUVID